On Our Way To The Unthinkable

quoth the raven's Photo
by quoth the raven
Tuesday, Jan 17, 2023 - 13:14

Submitted by QTR's Fringe Finance

For the second time in as many business days, I wanted to write today about developments that reinforce an investment idea I was recently considering.

Except with this piece, I’m not talking about gold or the macro trade: this is about a far more speculative idea that I think has a much more pronounced risk reward profile.

Days ago, I wrote this article, raising serious questions about potential coming culpability for several entities in the event that the public, and then the market, realizes (due to evidence) that the mRNA vaccines that were widely distributed to billions of people may not have been as safe or harmless as we were told. After all, we already know for sure they aren’t as effective as we were told they would be.

In just the 96 short hours since I first brought up the admittedly high-risk investment idea, a number of developments have taken place that I wanted my readers to be aware of because I believe they serve as several of a very long string of waypoints that could eventually end up with us waking up one day to a profound change in how the market looks at several companies. If you haven’t yet, you should read my first article about the idea here: Betting On The Unthinkable

Now, what else has developed that would lead me to believe that the vaccines could be at risk moving forward?

First there was new research out of Germany, published in the peer-reviewed journal Frontiers in Immunology, that revealed that mRNA booster shots are prompting the body to make different, “less effective” antibodies. Alex Berenson over at Unreported Truths wrote about the new research:

The new paper found that months after the second mRNA dose, people began to produce more of an antibody subclass called IgG4. IgG4 is usually the least common of the subtypes. It does not trigger a strong immune response after it latches to the virus.

The change was particularly obvious in people who had not been infected before receiving the vaccine, the researchers found.

The change also appeared to be dose-related. It occurred more strongly in people who had received the Moderna jab, which contains more than three times the mRNA as the Pfizer shot. (The fact that the other group of researchers found the change accelerated after a third shot is also evidence of a dose-response relationship.)

He continued: “Taken together, those findings suggest strongly that the immune system change to produce this weaker antibody is a protective response to an abnormality caused by the mRNAs. The long-term impact of the switch to IgG4 antibodies is unclear.”

Additionally, there has been new research published in the peer-reviewed European Journal of Pediatrics that shows 17% of teenagers - who shouldn’t even be getting the jab to begin with due to their disproportionately low risk for Covid complications versus the common flu - have had heart symptoms after getting their second Pfizer mRNA jab.

On top of that, we also find out from Berenson that “Pfizer’s bivalent Covid booster raised the risk of stroke for people over 65, according to a federal database that the government considers the gold standard for tracking vaccine side effects.”

All of these developments have come over the last week. As Berenson astutely alludes to, these are simply more “details” we’ll be figuring out well after we’ve jabbed billions of people.

But what's the investment idea here? (READ THIS FULL ARTICLE HERE TO FIND OUT). 


Contributor posts published on Zero Hedge do not necessarily represent the views and opinions of Zero Hedge, and are not selected, edited or screened by Zero Hedge editors.